Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programGiuseppe Procopio, Francesca Rastelli, Alberto F. Sobrero et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 140
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trialRoberto Labianca, Alberto Zaniboni, Alberto F. Sobrero et al.|Annals of Oncology|2010Cited by 110
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Diana Giannarelli, Alice Lunghi et al.|Lung Cancer|2019Cited by 42
Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programmeE.H. Baldini, Diana Giannarelli, Alessandro Lunghi et al.|Annals of Oncology|2018Cited by 1